Citi lowered the firm’s price target on Galera Therapeutics to $12 from $18 and keeps a Buy rating on the shares. The analyst updated the model to reflect the Q4 results.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRTX:
- Galera Therapeutics announces presentation of analysis of Phase 3 ROMAN trial
- Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
- These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
- Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
- Galera Therapeutics reports Q4 EPS (58c), consensus (54c)